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INTRODUCTION
Primitive endemic mycoses traditionally include
histoplasmosis, coccidioidomycosis, blastomy-
cosis and paracoccidioidomycosis.
Coccidioidomycosis, caused by Coccidioides im-
mitis, is mainly found in the South-Western USA,
where the incidence of the infection has increased
4-fold in the last 10 years (Parish and Blair, 2008).
The peculiar climatic conditions of these areas,
along with natural forces (dust storms, earth-
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quakes, etc.) and the anthropogenic disturbance of
the soil, are having a great impact on the arthro-
conidia dispersion (Comrie, 2005) and the in-
creased incidence of infection. Interestingly, cer-
tain ethnic groups have been shown to be more at
risk of developing the disease (Crum et al., 2004).
Histoplasmosis, caused by Histoplasma capsula-
tum, is the most common and world-wide dif-
fused primitive mycosis. Besides of being scat-
tered in microfoci in Asia and Africa, where H.
capsulatum var duboisii is well known, H. capsu-
latum var capsulatum (Kauffman, 2007) is high-
ly endemic in the mid-Western and South-
Eastern USA (Guimarães et al., 2006). Also in
Europe, H. capsulatum has been described, al-
though its endemicity and/or imported origin re-
mains to be established (Kauffman, 2007).
Overall, this pathogen is the main responsible for
A protein microarray containing fungal antigens (the “mycoarray”) has been set up to provide rapid and appropriate
serodiagnosis of primitive endemic mycoses, an important cause of morbidity and mortality in an increasingly high
number of patients. The mycoarray consists of three antigen extracts (histoplasmin, coccidioidin and Coccidioides “TP”)
and antibody dilution curves were spotted on microarray slides. The arrays were processed with coccidioidomycosis
and histoplasmosis patients’ sera or with control sera and the occurring immunocomplexes were detected by indirect
immunofluorescence. In agreement with clinical and microbiological diagnosis, the results distinguished between
histoplasmosis and coccidioidomycosis patients. In addition, the assay could clearly discriminate between IgM and
IgG antibody reactivity. No reactivity was ever observed in the arrays processed with negative control sera. Therefore,
this pilot study demonstrates that the “mycoarray” is sensitive and specific enough to discriminate between healthy
individuals and patients with histoplasmosis or coccidioidomycosis. Because of miniaturization and multiparametricity,
the new assay cuts costs and processing time. Thus, once clinically validated and implemented as a large-scale array,
the “mycoarray” will be ready to be applied to the daily clinical practice.
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respiratory primitive fungal disease(s): histo-
plasmosis affects healthy individuals and, more
importantly, immunocompromised patients,
where it may occur either as primary infection
following direct exposure to the pathogen or as
reactivation of a latent infection, acquired years
before (Ashbee et al., 2008). The majority of in-
fected individuals develop a mild subclinical in-
fection, which often remains undiagnosed. When
symptomatic, the pulmonary infection may range
from an influenza-like illness to a progressive
pneumonia, which evolves as a chronic cavitary
pulmonary disease or even as a highly lethal dis-
seminated infection, especially in immunocom-
promised patients, including individuals with
AIDS (Goodwin Jr. et al., 1981; Kauffman, 2007)
and patients receiving potent immunomodula-
tors (Deepe, 2007). 
Given the lack of specific clinical manifestations
in immunocompetent subjects and the severity
of the diseases in susceptible hosts, a quick and
early laboratory diagnosis is crucial in order to
initiate a suitable therapeutic protocol (Yeo and
Wong, 2002). In particular, because of their nat-
urally low frequency rate, clinical cases occurring
outside the endemic areas are often diagnosed
only at late stages of the disease. A common fea-
ture of primitive mycoses, such as coccid-
ioidomycosis and histoplasmosis, is their capac-
ity to elicit a strong humoral immune response;
therefore, the detection of specific serum anti-
bodies can be considered a relevant diagnostic
parameter (Laniado-Laborín, 2007). For exam-
ple, the identification of anti-Coccidioides IgM or
IgG antibodies is particularly useful in the diag-
nosis of coccidioidomycosis, also because of the
lack of other rapid diagnostic approaches and the
limitations of the culture methods (Wheat,
2006a). By conventional assays, such as comple-
ment fixation (CF), double immunodiffusion (ID)
and enzyme immunoassays (EIA), anti-
Coccidioides and anti-Histoplasma antibodies
may be detected (Wheat, 2003). Nevertheless,
each of these methods suffers from one or more
drawbacks: ID provides only qualitative results
(Galgiani, 1992); both ID and CF suffer from low
sensitivity (Wheat, 2007), whereas EIAs are more
sensitive, but less specific, especially in endemic
areas (Wheat, 2006b). Lastly, they all take a long
time to provide definitive results, especially ID
and CF (Pappagianis and Zimmer, 1990).
Recently, the development of protein microarray
technology, a miniaturization of ligand-binding
assays brought into an array format (Ekins et al.,
1990), has led to multiple applications both in re-
search and diagnostics. Specifically, microarray
immunoassays have been described for the de-
tection of specific antibody profiles in allergies
(Bacarese-Hamilton et al., 2002), autoimmune
disorders (Joos et al., 2000) and infectious dis-
eases, including mycoses (Bacarese-Hamilton et
al., 2004; Ardizzoni et al., 2009; Mochon et al.,
2010), thus providing novel and promising diag-
nostic tools.
This paper describes the development of a novel
serological test, the protein “mycoarray”, for the
diagnosis of primitive endemic mycoses, namely
histoplasmosis and coccidioidomycosis. The “my-
coarray” is a serological assay built up on a pro-
tein microarray platform. It is based on a chip
containing 3 relevant fungal extracts (Coccidioides
immitis “TP” antigen, coccidioidin and histo-
plasmin) along with IgM and IgG dilution curves,
used as internal calibration system. The protein
“mycoarray” has been proven to discriminate
healthy individuals from patients with histoplas-
mosis or coccidioidomycosis, according to their
humoral immune responses.
MATERIALS AND METHODS
Antigens
Antigens were supplied by Meridian Bioscience
Europe S.r.l (Milano, Italy): 2 different formula-
tions of Coccidioides immitis, the early antigen
(Coccidioides “TP”) and the late and highly im-
munogenic antigen (coccidioidin or Coccidioides
“F”, a purified cultural filtrate at concentration
of 100 units/ml); histoplasmin, a purified mycelial
cultural filtrate from the growth of Histoplasma
capsulatum, containing both “H” and “M” anti-
gens.
Antibodies and fluorescent labels
Human IgM and IgG were purchased from Sigma
Chemical Company (St. Louis, MO, USA). Before
being printed, the IgM antibodies were diluted in
1X PBS containing 0.1 g/l sodium dodecylsul-
phate, and the IgG in 1X PBS containing 0.1 g/l
sodium dodecysulphate and 50 g/l sucrose. Anti-
human IgM polyclonal antibody was purchased
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from Jackson Immuno Research Europe
(Newmarket, Suffolk, UK). Anti-human IgG mon-
oclonal antibody was provided by Radim S.p.a.
(Roma, Italy). Secondary antibodies were fluo-
rescently labelled with Alexa Fluor 555 Protein
Labeling Kit (Invitrogen). Purified goat IgG
(Pierce) and Alexa 647-labelled anti-goat IgG
(Invitrogen) were used for the initial optimiza-
tion of the array’s spotting conditions.
Serum samples
Six serum samples, collected in Northern Italy
from patients with primitive mycoses, were em-
ployed. Details concerning each patient’s clinical
history are given in table 1. All sera were previ-
ously tested both for the anti-C. immitis and an-
ti-H.capsulatum antibodies using the double dif-
fusion test according with the Oudin and
Outcherlony technique (Fungal Immunodiffusion
System, Meridian Bioscience Europe S.r.l.).
Control sera, collected from 15 healthy donors,
were run in parallel. Goat reference serum sam-
ples, positive and negative for the 3 antigens, were
purchased by Meridian Bioscience Europe S.r.l.
and used for the initial optimization of the array’s
spotting conditions.
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TABLE 1 - Clinical and laboratory data relative to the 6 patients included in the study.
Patient Case-history Haematological X-ray or Clinical Serology Culture Histology Clinical Therapy
parameters computed symptoms (ID) diagnosis
tomography
1 Italian, Onset C Reactive Chest Present Anti- C. Inmitis Coccidioides Invasive Itraconazole
Man 30 days Protein nodular coccidioidin in BAL BAL positive coccidioido-
after increased, lesions antibodies mycosis
returning hypereosi-
from Arizona, nophilia
USA
2 Italian, Onset C Reactive Chest Present Anti Not Not done Invasive Itraconazole
Man 20 days Protein nodular H. capsulatum available histoplasmosis
after increased lesions (“M” band)
returning antibodies
from Otonga, 
Ecuador
3 Italian, Onset C Reactive Chest Present Anti Not Not done Invasive None
Man 30 days after Protein and nodular H. capsulatum available histoplasmosis
returning AST/ALT lesions (“M” band)
from Otonga, increased antibodies
Ecuador
4 Italian, Immuno- Not available Not Present Anti H. capsulatum Not available Invasive Liposomal
Man suppressed available H. capsulatum in blood histoplasmosis Amphotericin
(“M” band) B
antibodies
5 Ivorian, HIV+ Not available Abdominal Initially Anti Not available Not available Invasive Liposomal
Man adenopathy present, H. capsulatum histoplasmosis Amphotericin
later healed (“M” band) B
antibodies
6 Liberian, HIV+, CD4 counts: Chest and Present Not assessed Not available Histoplasma Invasive Ambisone
Man Kaposi’s 20 cells/µl; CNS nodular bone marrow histoplasmosis then
sarcome viral load: lesions positive Fungizone
1455308 
copies/ml; 
pancytopenia: 
1020 WBC
Preparation of microarrays
Fungal antigens, serially diluted human antibod-
ies (IgM and IgG) and carry-over controls were
printed onto aldehyde glass microscope slides
(CEL Associates, Houston, TX, USA) using com-
puter controlled high speed robotics (MicroGrid
II BioRobotics, Genomic Solutions Inc., MI,
USA). Briefly, the solutions were transferred from
384-well microtiter plates (Porvair Sciences Ltd.,
Shepperton, UK) onto glass slides using stainless
steel solid pins of 200 µm diameter, where each
pin is estimated to transfer about 1 nl of sample
onto the slide. The low density arrays consisted of
7x7 matrices that included: 
1) the 3 fungal antigens printed in 4 replicates;
2) human IgM and human IgG antibody dilution
curves in duplicate;
3) negative controls;
4) signal controls;
5) carry-over controls (blanks).
Printing was performed inside a cabinet at 25°C
and 55% humidity. These conditions were con-
stanly monitored by thermohygrometers. Printed
slides were kept for an additional 12 hours in-
side the cabinet prior to removal and were sub-
sequently stored in boxes, at room temperature,
in presence of silica gel bags (Sigma Chemical
Company) and used within 90 days of being
printed.
Processing of microarray slides
Printed slides were incubated for 1 hour at room
temperature with 200 µl of a solution containing
20 g/l BSA in 1X PBS in order to prevent non-
specific antibody binding. An adhesive square-
shaped frame (Gene Frame, ABgene Limited,
Epsom, UK) was stuck onto the slide surface to
contain samples and reagents within the array
area. The serum samples were diluted 1:100 (for
the IgM test) and 1:200 (for the IgG test) in an
appropriate diluent buffer (2X PBS, 10 g/l BSA,
0.1 ml/l Tween 20) and allowed to react with the
array for 15 minutes at room temperature in a
humid chamber (100 µl of diluted sample per ar-
ray). Slides were washed with 1X PBS, 0.1 ml/l
Tween 20. To reveal IgM or IgG bound to the
printed antigens, the slides were incubated for 20
minutes with Alexa 555-labelled anti-human IgM
or with Alexa 555-labelled anti-human IgG; the
secondary antibodies were diluted in the same
diluent buffer employed for serum samples (see
above) to a final concentration of 1.5 µg/ml (an-
ti-human IgM) and 6 µg/ml (anti-human IgG);
100 µl of diluted secondary antibody per array
was added. Before reading the fluorescence in the
scanner, the slides were washed again and dried
by spinning them for 2 minutes in a centrifuge
at 3700 rpm at room temperature.
Data collection and analysis
The fluorescent signal was detected by reading
the slides in a ScanArray Gx scanner (Perkin-
Elmer, Cambridge, UK). The signal from each ar-
ray component was visualized in a pseudo-color
scale corresponding to increasing fluorescence,
where a white spot indicates a saturated signal
and spots which are coloured in red, yellow, light
green, dark green, correspond to a progressively
decreasing signal; blue and black spots are in-
dicative of very low and absent signal respective-
ly. Images generated were saved as TIFF files and
quantified with the ScanArrayExpress™ software,
provided by Perkin-Elmer.
Reference human IgM and IgG dose-response
curves were fitted using a Microsoft Excel linear
curve fit. The amounts of IgM and IgG in the sera
were determined by interpolating the photo-mul-
tiplier counts, collected at the microbial antigen
spots, with the corresponding human antibody
dilution curves.
In order to define the serological results obtained
with the microarray system, cut-off values were
determined for all the antigens of the panel, by
calculating the average mass of antibody bound
to the antigens + 2 standard deviations of the 15
negative control sera. The cut-off values were dif-
ferent for every antigen and for the 2 assays (IgG
and IgM). Therefore, all the sera with a reactivi-
ty below the cut-off value were considered nega-
tive, while all the sera with a reactivity above the
cut-off value were scored as positive.
RESULTS
Initial experiments were carried out to set up the
spotting conditions and processing protocol to be
used in the “mycoarray” assay, namely to estab-
lish the best condition for each antigen to form
immunocomplexes with its specific antibodies.
In particular, histoplasmin, coccidioidin and
Coccidioides “TP” antigen were spotted undiluted
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and serially diluted, both in distilled water and
in PBS. The chip was then processed with goat
reference positive and negative sera, followed by
fluorophore-labelled anti-goat IgG. These opti-
mization experiments allowed us to establish that
the array’s best performance was achieved when
histoplasmin and Coccidioides “TP” antigens were
spotted undiluted, and coccidioidin was diluted
1:10 in PBS (data not shown).
In order to assess anti-Histoplasma and anti-
Coccidioides antibodies in human sera, the ar-
rays, generated as above, were processed with
sera from patients affected by coccidioidomyco-
sis or histoplasmosis and then exposed to Alexa
555-labelled anti-human IgM or anti-human IgG.
Figure 1 shows 4 representative images of arrays
processed with sera from patients with coccid-
ioidomycosis (top arrays) or histoplasmosis (bot-
tom arrays). The following results were observed.
First, the test showed antibody-class specificity:
the arrays processed with anti-human IgM re-
turned a fluorescent signal only from the IgM
calibration curves (Figure 1A, blue frames); sim-
ilarly, the arrays processed with anti-human IgG
returned a fluorescent signal only from the IgG
calibration curve (Figure 1B, red frames).
Second, both Coccidioides antigens (Figure 1A,
top array, green frames) revealed high IgM reac-
tivity in the serum from the patient with coccid-
ioidomycosis, whereas no reactivity was ob-
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FIGURE 1 - A: Examples of IgM reactivity against Coccidioides immitis (top array) and Histoplasma capsulatum
(bottom array) as assessed by “mycoarray”. B: Examples of IgG reactivity against Coccidioides immitis (top array)
and Histoplasma capsulatum (bottom array) as assessed by “mycoarray”. IgM dilution curves are surrounded by blue
frames; IgG dilution curves are surrounded by red frames; green and yellow frames indicate Coccidioides antigens
and histoplasmin respectively.
served in this same patient from histoplasmin
(Figure 1A, top array, yellow frame). Third, up-
on assessment of IgG reactivity on this same
serum sample, no detectable signal was record-
ed from the Coccidioides antigens (Figure 1B, top
array, green frames). Fourth, the serum from the
histoplasmosis patient showed high and specif-
ic reactivity only against the histoplasmin spots,
both in terms of IgM (Figure 1A, bottom array,
yellow frame) and IgG (Figure 1B, bottom array,
yellow frame) antibodies. 
Using the “mycoarray” assay, 6 serum samples
from patients with histoplasmosis or coccid-
ioidomycosis, recently diagnosed in Northern
Italy, and 15 serum samples from healthy indi-
viduals were assessed. As summarized in table 1,
out of the 6 patients, 3 were travellers (patients 1-
3), 1 was pharmacologically immunosuppressed
(patient 4) and 2 were HIV-positive (patients 5
and 6). Laboratory data and clinical features led
to definitive diagnosis of invasive mycoses.
Figure 2 shows quantitative results obtained on
the 6 patients by “mycoarray”. For each fungal
antigen and for both the IgM (left panels) and
IgG (right panels) tests, the cut-off values (verti-
cal lines) were calculated as detailed in Materials
and Methods. As shown in figures 2A and 2C, the
IgM reactivity against Coccidioidin and
Coccidioides “TP” respectively was detected only
in serum 1. Moreover, histoplasmin specific IgM
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FIGURE 2 - Serological reactivity of 6 serum samples collected from patients affected by primitive mycoses, as as-
sessed by “mycoarray”. A, B: IgM and IgG antibodies against coccidioidin; C, D: IgM and IgG antibodies against
Coccidioides TP antigen; E, F: IgM and IgG antibodies against histoplasmin. Vertical lines represent the cut-off lim-
its. The horizontal columns depict the mass of bound antibody and the bars indicate the standard deviations (four
replicates of two independent experiments).
antibodies were detected in sera 2, 3 and 4
(Figure 2E). Samples 5 and 6 were IgM negative
for all the antigens (Figure 2A, 2C and 2E).
Concerning the IgG test, no sera showed any IgG
reactivity against coccidioidin and Coccidioides
TP antigen (Figure 2B and 2D), except for serum
2 that showed IgG antibodies against-coccidioidin
(Figure 2B). Furthermore, histoplasmin provided
clear IgG positive results in all the sera, except
for sera 1 and 6 (Figure 2F). No antibody reac-
tivity against any of the fungal antigens was ever
detected in the 15 negative control sera from
healthy donors, either in the IgM or in the IgG
test (data not shown).
Table 2 summarizes the clinical diagnosis and
serological results obtained by the “mycoarray”.
On the one hand, the patient with coccid-
ioidomycosis (patient 1) was identified as posi-
tive in terms of IgM reactivity, by both the coc-
cidioidin and the Coccidioides TP antigen, where-
as no reactivity was detected in the IgG test. In ad-
dition, no reactivity was detected against histo-
plasmin in this same patient. On the other hand,
when the sera from patients with histoplasmosis
were considered (patients 2-6), the “mycoarray”
revealed IgM reactivity in sera 2, 3 and 4. These
same sera were also highly positive in terms of
anti-Histoplasma IgG response; moreover, signif-
icant levels of IgG were revealed in all the other
samples from histoplasmosis patients, with the
exception of serum 6 that showed no antibody
reactivity at all. 
DISCUSSION
Coccidioidomycosis and histoplasmosis are prim-
itive mycoses still characterized by a strong en-
demic feature; yet, the increased frequency of
worldwide travel and immigration are transfer-
ring the incidence of clinical cases outside en-
demic areas. Notwithstanding the occurrence of
several imported cases of primitive mycoses re-
cently diagnosed in Northern Italy, the incidence
of these infections is often underestimated
(Farina et al., 2005; Galetta et al., 2007). This is
mainly due to the still low frequency of clinical
cases recorded in this country, together with sev-
eral drawbacks of the available diagnostic meth-
ods (Pappagianis and Zimmer, 1990; Galgiani,
1992; Wheat, 2006b; Wheat, 2007).
This paper describes the “mycoarray”, a novel lab-
oratory tool that couples the usefulness of sero-
logical investigations in the diagnosis of endem-
ic mycoses with the advantages of the protein mi-
croarray technology. The array, containing 2 dif-
ferent antigens from C. immitis (coccidioidin and
Coccidioides TP antigen) and an antigenic prepa-
ration from H. capsulatum (histoplasmin), has
been used to assess serum samples from 6 pa-
tients clinically diagnosed with invasive mycoses,
as documented by ID assay, conventional culture
procedures and/or histology. As detailed above,
when assessing serum from patient 1, who had
been hospitalized for invasive coccidioidomyco-
sis (Rossanese A et al. 11th Conference of the
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TABLE 2 - Summary of the 6 patients’ serological reactivity against fungal antigens, 
as assessed by “mycoarray”.
Clinical diagnosis Serum sample IgM response to IgG response to
Cocca TP Histo Cocc TP Histo
Coccidioidomycosis 1 ++ + - - - -
Histoplasmosis 2 - - + + - ++++
“ 3 - - +++ - - +++
“ 4 - - +++ - - +++
“ 5 - - - - - +
“ 6 - - - - - -
aCocc = coccidioidin; TP = Coccidioides TP antigen; Histo = histoplasmin.
International Society of Travel Medicine,
Budapest, Hungary, May 24-28, 2009, Abstract
PO06.22), the assay reveals a clear IgM response
(well above the cut-off values) against
Coccidioides TP and a much higher signal against
coccidioidin. Notoriously, when an infection by
C. immitis is contracted, the first detectable anti-
bodies are IgM against “TP”, which appear with-
in several days from the infection and gradually
wane away within a few months; the subsequent
IgG response appears within 1 to 3 months, per-
sists for long time and is mainly directed against
the F antigens (coccidioidin), known to be high-
ly immunogenic (Smith et al., 1956; Sawaki et al.,
1966; Bronnimann and Galgiani, 1989; Cox, 1989;
Pappagianis and Zimmer, 1990; Anstead and
Graybill, 2006). The present results obtained with
the “mycoarray” show that TP and coccidioidin
are both effective in detecting IgM response,
namely both antigens are good “capture” systems
in revealing IgM positive individuals (Figure 2A
and 2C). 
In contrast, when evaluating the IgG reactivity,
neither coccidioidin nor TP reveal any positivity
in patient 1, which indicates that he is experi-
encing a very recently acquired infection.
Moreover, the lack of IgM reactivity against coc-
cidioidin and Coccidioides “TP” in all the other
patients’ sera, as well as in all the healthy control
subjects (data not shown), demostrate the speci-
ficity of the assay. Furthermore, histoplasmin al-
lows detection of IgM reactivity in sera 2, 3 and
4, implying that histoplasmosis has recently been
acquired by these patients. Interestingly, the ID
assay in these patients provided IgM negative re-
sults (no “H” bands). Our findings imply a better
performance of the “mycoarray” in terms of en-
hanced sensitivity with respect to the conven-
tional serological assays. In contrast, patients 5
and 6 show no IgM reactivity (Figure 2E); these
data may be related to either no recent contact
with the pathogen or to hyporesponsiveness of
the host. 
Concerning the IgG test, no reactivity was de-
tectable against both C. immitis antigens (Figure
2B and 2D) with the exception of anti-coccid-
ioidin IgGs observed in serum 2 (Figure 2B). This
serum was collected from a patient clinically di-
agnosed for histoplasmosis. Accordingly, the “mi-
coarray” has revealed high IgM/IgG reactivity
against histoplasmin. The unexpected presence
of anti-coccidioidin antibodies in patient 2 may
be interpreted in two different ways. First, they
may represent a long-lasting memory of a previ-
ous infection; this is in line with the lack of IgM
and with a report by Cox (1989), which described
the persistency of anti-coccidioidin IgG for long
times after the infection/disease; second, the an-
ti-coccidioidin reactivity may be a false-positive
result due to a cross-reaction phenomenon, al-
ready described (Cox, 1979). While we tend to ex-
clude this last hypothesis, since none of the oth-
er sera from histoplasmosis patients show any
positivity for Coccidioides antigens, we rather pro-
pose the “mycoarray” as a sensitive tool, capable
of providing a very informative picture of the clin-
ical history of an individual by a careful evalua-
tion of his antibody repertoire. 
As regards anti-Histoplasma IgG reactivity, anti-
histoplasmin IgG antibody titers were detectable
in patients 2-5 (Figure 2F), in line with the results
of the ID test, where clear “M” bands were ob-
served (Table 1). The negative results observed in
patient 6 are likely related to his AIDS condition:
no antibody response is detectable, likely because
his immune system is deeply hampered by the
HIV infection. Taken together, our results point
out to the “mycoarray” as a more sensitive diag-
nostic tool for the serology of primitive endemic
mycoses. 
Protein microarrays enable sensitive and specif-
ic detection of serum antibodies (Joos et al., 2000;
Bacarese-Hamilton et al., 2002; Bacarese-
Hamilton et al., 2004; Ardizzoni et al., 2009;
Mochon et al., 2010). In particular, quantitative
evaluation of specific IgG and IgM against
pathogens responsible for vertically transmitted
infections has recently been described (Ardizzoni
et al., 2009). The main advantages of serological
screening by microarray are multiparametricity
and miniaturization. The multiparametricity im-
plies deposition onto the same microscope slide,
of an enormous number of determinants, by spot-
ting many antigens from different pathogens, dif-
ferent antigenic preparations from the same mi-
crobial agents, and many replicates of the same
antigen. The miniaturization allows a reduction
in costs (minimal amounts of antigens, serum
samples and reagents) as well as in timing. Here,
we demonstrate that the “mycoarray” assay al-
lows identification of Histoplasma- and
Coccidioides-positive subjects, according to their
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serological response. Although aware of the lim-
itations of the present study (3 fungal antigens, 6
patients), we provide initial evidence on the use-
fulness of the “mycoarray” in clinical mycology
laboratories since, unlike conventional tests, it al-
lows low reagents/sera consumption in parallel
with rapid, one-shot and multiple determinations.
These features may become particularly impor-
tant in non-endemic countries where infected
subjects are often diagnosed at later stages of the
diseases. By employing an assay such as the “my-
coarray”, these fungal infections may be spotted
earlier, even before disease onset. 
In conclusion, we have described a novel sero-
logical assay sensitive, specific, rapid and multi-
parametric, deserving consideration also for fu-
ture applications, such as:
1) its enlargement by addition of other serologi-
cally relevant fungal antigens;
2) inclusion of antibodies as “capture molecules”
for specific fungal antigens that will make this
test suitable also for diagnosis during the ini-
tial phases of infection, when antigenemia is
a most valuable diagnostic parameter;
3) use of highly sensitive detection systems, such
as the tyramide amplification already suc-
cessfully applied to the allergen microarrays
(Bacarese-Hamilton et al., 2002), which may
facilitate serological analysis, especially for
critical patients where antibody titers are very
low.
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